Spyre Therapeutics rises as investors chase SKYWAY acceleration and post-SPY001 data momentum
Spyre Therapeutics (SYRE) is up about 3% today as investors continue to position around its accelerated SKYWAY rheumatoid arthritis timeline, with topline data now expected in Q3 2026 after enrollment was completed. The stock has stayed bid following April’s positive SPY001 Phase 2 ulcerative colitis induction data and subsequent analyst target raises.
1) What’s moving SYRE today
Spyre Therapeutics shares are higher today as the market continues to trade the company’s 2026 catalyst calendar, with particular focus on the SKYWAY basket program after Spyre completed recruitment for the rheumatoid arthritis sub-study and pulled forward expected Week 12 topline results into Q3 2026. The move looks like follow-through demand rather than a single new headline, as investors keep layering in exposure to nearer-dated readouts in inflammatory and rheumatic indications. (tipranks.com)
2) The broader catalyst backdrop: SPY001 UC readout still driving sentiment
The current bid also reflects lingering optimism from Spyre’s April 13, 2026 update where SPY001 posted positive Part A induction topline results in the Phase 2 SKYLINE trial in moderate-to-severe ulcerative colitis, including meeting the primary endpoint (Robarts Histopathology Index reduction at Week 12). That dataset reset expectations for the program and remains the anchor for the bull case as investors look toward subsequent cohorts and additional proof-of-concept readouts in 2026. (sec.gov)
3) Street support and positioning after the April financing
After the UC data, multiple analysts raised targets in mid-April, reinforcing the perception that Spyre’s probability-adjusted pipeline value improved. At the same time, the company completed an upsized equity offering in April, increasing cash runway but also adding a supply overhang that can amplify day-to-day swings as buyers absorb shares and traders reposition around upcoming trial updates. (stockanalysis.com)